BRCA1 and ovarian carcinoma: We were unable to test for effect modification by pathogenic variants (ie, BRCA1/BRCA2); randomized clinical trials of aspirin use in these specific subgroups are ongoing.20 This study leveraged harmonized genetic and epidemiologic data from 8 ovarian cancer studies, a data resource that allowed for assessment of the association of aspirin with ovarian cancer across strata of the PGS.